In the last week, the United States market has remained flat, yet it has achieved a remarkable 24% increase over the past year with earnings projected to grow by 15% annually in the coming years. In this dynamic environment, identifying stocks with strong potential involves seeking out companies that are not only resilient but also poised to capitalize on these favorable growth trends.
Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
---|---|---|---|---|
Eagle Financial Services | 170.75% | 12.30% | 1.92% | ★★★★★★ |
Morris State Bancshares | 10.20% | -0.28% | 6.97% | ★★★★★★ |
Franklin Financial Services | 173.21% | 5.55% | -1.86% | ★★★★★★ |
Omega Flex | NA | 0.39% | 2.57% | ★★★★★★ |
Parker Drilling | 46.05% | 0.86% | 52.25% | ★★★★★★ |
First Northern Community Bancorp | NA | 7.65% | 11.17% | ★★★★★★ |
Teekay | NA | -3.71% | 60.91% | ★★★★★★ |
ASA Gold and Precious Metals | NA | 7.11% | -35.88% | ★★★★★☆ |
Pure Cycle | 5.31% | -4.44% | -5.74% | ★★★★★☆ |
FRMO | 0.13% | 19.43% | 29.70% | ★★★★☆☆ |
Click here to see the full list of 245 stocks from our US Undiscovered Gems With Strong Fundamentals screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Value Rating: ★★★★★★
Overview: IRADIMED CORPORATION develops, manufactures, markets, and distributes MRI-compatible medical devices and related accessories, disposables, and services in the United States and internationally with a market cap of $692.86 million.
Operations: IRADIMED generates revenue primarily from its patient monitoring equipment, totaling $71.31 million. The company's financial performance is reflected in its gross profit margin, which stands at 76.5%.
IRADIMED, a nimble player in the medical equipment sector, showcases a robust financial profile with no debt and high-quality earnings. Its earnings have grown 27.7% annually over the past five years, yet recent insider selling could signal caution. Trading at 45.4% below fair value estimates suggests potential upside, though its earnings growth of 14.1% lagged slightly behind industry peers last year. The company anticipates revenue between $72.7 million and $73.1 million for 2024 and has raised its EPS guidance to $1.49-$1.52, reflecting confidence in strategic initiatives like their new MRI-compatible pump launch slated for late 2025.
Simply Wall St Value Rating: ★★★★★★
Overview: Photronics, Inc. is a company that manufactures and sells photomask products and services across various regions including the United States, Taiwan, China, Korea, Europe, and other international markets with a market cap of approximately $1.51 billion.
Operations: Photronics generates revenue primarily from the manufacture of photomasks, with reported sales of $866.95 million. The company's financial performance can be analyzed through its net profit margin trends, which provide insight into profitability relative to total revenue.
Photronics, a nimble player in the semiconductor space, has no debt today compared to a 5.8% debt-to-equity ratio five years ago. Its earnings grew by 4.1% last year, outpacing the industry average of -3.6%. Despite significant insider selling recently, the company trades at nearly 30% below its estimated fair value and boasts high-quality earnings. While strategically expanding in China and investing $200 million into U.S. capacity for ICs, geopolitical risks could impact margins slightly as analysts foresee annual revenue growth of 6.3%, with profits reaching $151 million by late 2027.
Simply Wall St Value Rating: ★★★★★★
Overview: Perdoceo Education Corporation offers postsecondary education through online, campus-based, and blended learning programs in the United States, with a market cap of $1.73 billion.
Operations: The company generates revenue primarily from its two main segments: Colorado Technical University (CTU) with $446.73 million and American InterContinental University (AIUS) with $205.29 million.
Perdoceo Education, a small cap contender in the education sector, is trading significantly below its estimated fair value by 57.3%, presenting a potential opportunity for investors. Despite a recent earnings drop of 9% against an industry average growth of 34.8%, it remains debt-free with high-quality past earnings and positive free cash flow. The company reported third-quarter revenue at US$169.83 million and net income at US$38.26 million, slightly lower than the previous year’s figures but still maintaining profitability with basic EPS from continuing operations at US$0.58 compared to US$0.63 last year, indicating resilience amidst operational shifts and strategic acquisitions like the University of St Augustine aimed at diversifying revenue streams and improving efficiency through tech investments.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:IRMD NasdaqGS:PLAB and NasdaqGS:PRDO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。